Specific binding sites for 1-O-alkyl-sn-glyceryl-3-phosphorylcholine on intact human blood neutrophils

International Archives of Allergy and Immunology

Volumn 113, Issue 4, 1997, Pages 460-464

  Korth, Ruth Maria ^a,b  

^a Forsch in der Allgemeinmedizin FIDA   (Germany)

^b INSERM   (France)

Author keywords

Lyso paf; Lyso paf receptors; Neutrophils human; Platelet activating factor receptor; Protein kinase C

Indexed keywords

1 O ALKYLGLYCERO 3 PHOSPHORYLCHOLINE; FATTY ACID; LYSOPHOSPHOLIPID; SERUM ALBUMIN;

ALLERGY; ARTICLE; BINDING SITE; BLOOD DISEASE; CONTROLLED STUDY; EOSINOPHIL; HUMAN; HUMAN CELL; INFECTION; INFLAMMATION; MALE; MEMBRANE BINDING; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; SCATCHARD PLOT;

EID: 0030837112     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237623     Document Type: Article

References (26)

1. Polonsky J, Tence M, Varcnnc P, Das BC, Lunel J, Bcnvcniste J: Release of l-O-alkylgly-ceryl-3-phosphorylchollne, O-deacetyl platelet-activating factor from leukocytes: Chemical ionization mass spectrometry of phospholipids. Proc Natl Acad Sci USA. 1980;77:7019-7023.
2. Snyder F: Review article. Platelet activating factor: The biosynthetic and catabolic enzymes. Biochem J 1995;305:689-705.
3. Meade C, Hetter H, Kentpe R: Commentary. Biochemical pharmacology of platelet-activating factor (and paf antagonists) in relation to clinical and experimental thrombocytopenia. Biochem Pharmacol 1991;41:657-668.
4. Amoux B, Page CP, Denjcan A, Nolibc D, Mor-ly J, Benveniste J: Pulmonary effects of paf-acether in baboons. Inhibition by ketotifen. Am Rev Respir Dis 1988;137:855-860.
5. Cook RM, Musgrove NRJ, Smith H: Relationship between neutrophil infiltration and tissue eosinophilia in the rat. Int Arch Allergy Appl Immunol 1988:87:105-108.
6. Oishi K, Raynor RL, C'harp PA, Kuo JF: Regulation of protein kinase C by lysophospholipids. Potential role in signal transduction. J Biol Chem 1988;263:6865-6871.
7. Korth RM: Specific high affinity binding of platelet activating factor to intact human blood neutrophils and eosinophils. Int Arch Allergy Immunol 1996:110:124-131.
8. Korth R, Benveniste J: Lyso paf-accther (lyso paf) binding sites in human neutrophils (HN). FASEBJ 1992;6:A2188.
9. Korth R, Middeke M: Long time incubation of monocytic U 937 cells with LDL increases specific paf-accther binding and the cellular acctyl-hydrolase activity. Chem Phys Lipids 1991;59: 207-213.
10. O’Flaherty JT, Jacobsen DP, Redman JF: Bidirectional effects of protein kinase C activators. Studies with human neutrophils and platelet activating factor. J Biol Chem 1989:264:6836-6843.
11. Quinn MT, Parthasarathy S, Steinberg D: Lyso-phosphatidyl choline: A chemotactic factor for human monocytes and its potential role in atlic-rogenesis. Proc Natl Acad Sci 1988:88:2805-2809.
12. Kugiyama K, Kerns SA, Morrisctt JD, Roberts R, Henry PD: Impairment of endothelium-dependent arterial relaxation by lysolccithin in modified low-density lipoproteins. Nature 1990;344:160-162.
13. Vadas P, Pruzanski W: Biology of disease. Role of secretory phospholipasc A, in the pathobiol-ogy of disease. Lab Invest 1986;55:391-404.
14. Korth RM: US patent, 1992, No 5,346-894.
15. Korth RM: l-0-Alkyl-2-glycero-3-phospho-choline in the cerebrospinal fluid from psychiatric patients. Fur Neuro-psychopharmacol. in press.
16. Hattori M, Adachi H, Tsujimoto M, Arai H, Inoue K: Miller-Dickcr lisscnccphaly gene encodes a subunit of brain platelet-activating factor. Nature 1994;370:216-218.
17. Lekka ME, Tsoukatos D, KapoulasVM: In vivo metabolism of platelet activating factor (l-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by the protozoan Tetrahymenapyrifonnis. Bio-chim Biophys Acta 1990;1042:217-220.
18. Korth RM, Hirafuji M, Benveniste J, Russo-Marie F: Human umbilical vein endothelial cells: Specific binding of platelet-activating factor and cytosolic calcium flux. Biochem Pharmacol 1995;49:1793-1799.
19. Korth R, Bidault J, Palmantier R, Bcnvcniste J, Ninio E: Human platelets release a paf-aeeth-er:acetylhydrolase similar to that in plasma. Lipids 1993;28:193-199.
20. Stremler KE, Stafforini DM, Prescott SM, Zim-mennan GA, McIntyre TM: An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolasc front human plasma. J Biol Client 1989:264: 5331-5334.
21. 2‘indicators with greatly improved fluorescence properties. J Biol Chem 1985:260:3440-3450.
22. O'Flaherty JT, Surles J, Redman J, Jacobson D, Piantadosie C, Wykle RL: Binding and metabolism of platelet-activating factor by human neutrophils. J Clin Invest 1986;78:381-388.
23. Kunz D, Gerard N, Gerard C: The human leukocyte platelet-activating factor receptor. J Biol Chem 1992;267:9101-9107.
24. Korllt R, Hirafuji M, Lalau Kcraly C, Dclauticr D, Bidault J, Benveniste J: Interaction of the paf antagonist WEB 2086 and its hctrazepinc analogues with human platelets and endothelial cells. Br J Pharmacol 1989;98:653-661.
25. Korth R, Nunez D, Bidault J, Benveniste J: Comparison of three paf-acether receptor antagonist ginkgolides. Eur J Pharmacol 1988; 152:101-110.
26. Korth RM: Verwendung von paf-Acether-An-tagonisten zur Herstellung eines Arzneimittels und Verfahren zu deren Wirksamkeitsbestimmung, Eur Patent, 1987. No 0312913.